Probi
351
SEK
0 %
PROB
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
Be the first to follow this company
0%
+32.45%
+30.48%
+31.46%
+68.75%
+72.91%
+74.63%
-15.73%
+35.26%
+3,172.01%
www.probi.com/investor-relations
Probi is a biotechnology company. The company is particularly focused on the research and development of probiotics, a bacterium that is found in the human intestinal system. The research areas within the company include the gastrointestinal, immune system, metabolic syndrome, and stress and recovery. The company's customers include larger corporate customers active in the food industry. The company was founded in 1991 and is headquartered in Lund.
Revenue
627.69M
EBIT %
1.8 %
P/E
237.16
Dividend yield-%
0.37 %
Target price
-
Recommendation
-
Updated
-
NASDAQ Stockholm
PROB
Daily low / high price
350 / 351
SEK
Market cap
4B SEK
Turnover
3.75M SEK
Volume
11K
Latest videos
Financial calendar
Annual report
2025-01-28
Interim report
2025-04-23
General meeting
2025-05-06
Interim report
2025-07-17
Interim report
2025-10-23
Major OwnersSource: Millistream Market Data AB
Owner | Capital | Votes |
---|---|---|
Symrise | 69.7 % | 69.7 % |
Fjärde AP-fonden | 9.3 % | 9.3 % |
Caceis Bank | 8.3 % | 8.3 % |
Avanza Pension | 0.6 % | 0.6 % |
J.P.Morgan SE, Luxembourg Branch, W8IMY/NQI | 0.5 % | 0.5 % |
The Bank of New York Mellon, W9 | 0.5 % | 0.5 % |
Nordnet Pensionsförsäkring AB | 0.3 % | 0.3 % |
Österlin, Claes | 0.3 % | 0.3 % |
SEB Sverige Indexnara | 0.3 % | 0.3 % |
ShowingAll content types
Probi's Board comments on Symrise's public takeover offer
Probis styrelse kommenterar offentligt uppköpserbjudande från Symrise
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools